Summarv It has been shown that some types of tumour cells produce actixated transforming grou-th factor beta-i (TGF-I1). How-ever. the mechanism for the actix-ation of TGF-i1 denived from tumour cells has not been fullv elucidated The present study w-as undertaken to characterise an activator of latent TGF-i1 secreted from a human gastric cancer cell line. KATO-I11 Western blot analyses using antibodies for TGF-pI. latency associated peptide (LAP) and latent TGF-0l-binding protein (LTBP) Kevwords: transforming 2rox-th factor beta-I. transforming Trowth factor beta-I activator: eastnc cancer
Transforming grouth factor beta-I (TGF-Pl). initialiv found as a transforming cytokine in tumour cells. is now-know-n to exert multiple functions includinz immunosuppression. fibrosis of tissue. myelosuppression. osteozenesis. angiogenesis. liver regeneration and mammalian development. It is usually secreted in an inactive form and subsequently activated at the site w-here it functions. The mechanism for this activation is thought to result from its modulation by plasmin (L-ons et al.. 1988: Sato and Rifkin. 1989) . cathepsin D (Lyons et al.. 1988) . endogl-cosidase and sialidase (Mivazono and Heldin. 1989). Usuallx-. intracellular TGF-P1 exists as a latent form which is composed of mature TGF-B1. amino-terminal remnant of TGF-i1 precursor called latency associated peptide (LAP) and latent TGF-0l-binding protein (LTBP) . and w-ide LAP-TGF-1 complexes show-no TGF-pl activitx. From certain types of tumour cells or normal diploid cells. howexer. an active form of TGF-PI from which LAP has been released is secreted into culture medium either spontaneously or on stimulation with v anous agents. However. few detailed studies have been devoted to the question of w-hether the active TGF-PI in the culture medium is actually released in an active form or is released in a latent form together xvith some activators. Takiuchi et al. (1992) demonstrated that a particular ty pe of Rous sarcoma virus-induced fibrosarcoma cells have in their conditioned medium the potential to convert latent TGF-PI to its active form. however the mechanism of its conversion has not been clarified. The present study-. for the first time. demonstrates that KATO-ITI cells derived from human gastric carcinoma secrete a senine protease. different from plasmin. plasminogen actixvator. cathepsin D. endoglvcosidase F or sialidase which activates a small latent TGF-pl complex co-secreted from the same cells.
Materials and methods

Cell culture
A human scirrhous gastnc cancer cell line. KATO-III (Sekiguchi et al.. 1978 TGF-PI (Derynk et al.. 1985) were svnthesised and immunised to rabbits. The antisera A-ere heat-inactix-ated (56°C. 30 min). and IgG w-ere prepared from these antisera by passing through protein A-Sepharose (Pharmacia Biotechnology.
Uppsala. Sweden). Amonz these three. anti-N 92 -103 antibodies were used as a neutralising antibody and anti-N 1 -15 antibodies for detection of TGF-1I (Terui et al.. 1990) in cell extracts by Aestem blot analy-sis as described below-.
Anti-LAP and anti-LTBP antibodies (MiN azono et al.. 1991) w-ere kindly provided by Dr K Miyazono. Ludw-iz Institute. Uppsala. Sw-eden. UWestern blot oft TGF-f. L.4P and LTBP To prepare cell extracts from KATO-II cells. 1 x 10 cells wxere homozenis'ed in phosphate-buffered saline containing 1 m-M phenylmethy lsulphonyl fluoride (PMSF) with a Dounce homozeniser (Wheaton Glass. Millivile. NJ. USA). Acidethanol treatment of the cellular extract was performed as previously described (Terui et al.. 1990 (Feinberg and Vogelstein. 1984) Gel chromatography An aliquot of 0.5 ml of conditioned medium or cell lysate prepared from KATO-I1I cells was fractionated (0.5 ml per tube) by gel chromatography on a SW3.000 column (Toyo Soda. Tokyo. Japan) using phosphate-buffered saline as eluent. Aliquots of 0.1 ml of the individual fractions. either alone or after addition of 0.1 ml of NRK49F conditioned medium containing latent TGF-P 1. were then incubated for 60 mn at 37C. after which TGF-PI activity was measured bv soft agar colony assay and radioreceptor assay.
Phvsicochemical and enzymatic treatments of TGF-PI (Figure 2 ). Non-acidified samples revealed several small peaks of activity, possibly representing the partial conversion of latent forms to active forms during the preparation of cell lysate and the chromatographic procedure by putative concomitant proteases as suggested by Wakefield et al. (1988) . Among the small peaks, the most prominent one was assumed to be that of mature TGF-PI since it was eluted at a fraction of molecular weight of 25 000 Da. In acidified samples, on the other hand, three new distinct peaks of activity appeared in relatively higher molecular weight fractions. The first peak at the void volume might be an aggregated form. The second main peak with molecular weight of 100 000 Da apparently corresponded to the small latent TGF-01 complex. These results indicate that TGF-PI in KATO-III cells is produced in a small latent form which was consistent with the results of Western blot analyses (Figure la and b) .
Identification of TGF-PI activator released bk KA TO-III cells
The fact that TGF-PI produced by KATO-III cells is present in a latent form within the cells but in an active form in the conditioned medium suggests either the presence of some co-factor which activates latent TGF-PI after it is secreted into the conditioned medium or an activation of TGF-PI during the secretion process. To examine these possibilities, conditioned medium from KATO-III cells was fractionated on gel chromatography (Figure 3a) and each fraction was added to conditioned medium from NRK49F cells containing latent TGF-PI (Figure 3b ). As shown in Figure 3b , three major peaks of TGF-PI activity were obtained and the first peak was eluted at the void volume, the second at around a molecular weight of 65 000 Da, and the third peak with smaller shoulder at a molecular weight of 25 000 Da. When the fractions of gel chromatography were tested for TGF-PI activity in the absence of NRK-49F medium, only two peaks at the void volume (peak 1) and at 25 000 Da (peak 3), were obtained which each appeared to represent an aggregated form and a mature form of TGF-f1 respectively, (Figure 3a) . Moreover, TGF-P1 activity in peak 2 (Figure 3b ) was neutralised by anti-TGF-Pl antibodies (Figure 3c ). It was therefore assumed that the fraction corresponding to peak 2 (-65 000) contained some factor which activated latent TGF-P1 from NRK-49F cells. This assumption was further confirmed by the fact that fractions containing peak 2 were able to activate as effectively as acid treatment, the latent TGF-P1 of KATO-III cell lysate fractionated on gel chromatography (Figure 2) . We therefore designated the fraction (peak 2. Figure 3b) as a TGF-Pl activator which strongly activated latent TGF-i1 from KATO-III or NRK-49F cells.
Physicochemical properties and enzYmatic analtses of the TGF-PI activator We attempted the characterisation of the TGF-PI activator from KATO-III cells by physicochemical and enzymatic treatment. The TGF-P1 activator in the peak 2 fraction in Figure 3b was partially inactivated by heat treatment at 56°C for 30 min or by acidification and completely by heat treatment at 100'C for 5 min. Inactivation of the factor was also brought about by treatment with trypsin, with nafamostat mesilate. a synthetic senine protease inhibitor and with DFP and PMSF, senine protease inhibitors. However, the activity of this factor was unaffected by treatment with pepstatin, an aspartase protease inhibitor, with EDTA. a metalloprotease inhibitor and with a2-plasmin inhibitor (Table II) . Neither plasmin nor plasminogen activator activity was detected in the conditioned medium from KATO-I1I cells. Moreover, the TGF-PI activator from KATO-III cells did not convert plasminogen to plasmin in the conditioned medium of NRK-49F cells (Table III) . Furthermore, this activator is more effective than some enzymes including plasmin. cathepsin D, endoglycosidase F or sialidase which have been reported as partial activators for latent TGF-B1 (Table IV) . These results suggest that the TGF-PI activator is an acid and heat-labile serine protease, different from plasmin. plasminogen activator. cathepsin D, endoglycosidase F or sialidase. Discussion TGF-P1 produced by cells or platelets is generally inactive and is somehow-conx-erted into an activ-e form at the site where it functions. Ho"ever. in some types of cells. particularl-in tumour cells. TGF-PI is found to be active in their conditioned medium and therefore can participate locally in Table II Physicochemical properties various pathological situations such as myelofibrosis in acute megakaryoblastic leukaemia (Terui et al.. 1990) . stromal induction in scirrhous gastric carcinoma (Mahara et al.. 1994 : Yoshida et al.. 1989 . autocrine growth and hypercalcaemia in adult T-cell leukaemia (Niitsu et al.. 1988) and immunosuppression in glioblastoma (Wrann et al.. 1987) .
However, whether the active TGF-PI in these media is indeed secreted from tumour cells as it is or is converted from a latent form by concomitantly secreted modulators (most plausibly some enzymes) is still unclear. We attempted to elucidate the above question using the KATO-I1I cell hne of human gastric cancer. We (Mahara et al.. 1994) and Ura et al. (1991) (Derynk. 1988; Rosenthal et al.. 1988) . Therefore, in the present study. we first proved that the activity of KATO-III conditioned medium manifested in the soft-agar colony assay was TGF-P1 by employing a radioreceptor assay (Table I) and by using neutralising anti-TGF-P1 antibodies. Next, the question of whether TGF-P1 is produced intracellularly in an active form or in a latent form in KATO-III cells was investigated. From the results of the radioreceptor assay of KATO-III cell lysate. intracellular TGF-PI was shown to be mainly in the latent form (Table I) .
With regard to the intracellular TGF-Bl. two different types of latent form have been so far identified (Miyazono et al.. 1988 : Wakefield et al.. 1988 : Takiuchi et al.. 1992 
